ES2124257T3 - Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores. - Google Patents

Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores.

Info

Publication number
ES2124257T3
ES2124257T3 ES92910345T ES92910345T ES2124257T3 ES 2124257 T3 ES2124257 T3 ES 2124257T3 ES 92910345 T ES92910345 T ES 92910345T ES 92910345 T ES92910345 T ES 92910345T ES 2124257 T3 ES2124257 T3 ES 2124257T3
Authority
ES
Spain
Prior art keywords
composition
equipment
tumor activity
tumors
stimulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910345T
Other languages
English (en)
Other versions
ES2124257T4 (es
Inventor
Tetsuhiko Shirasaka
Masakazu Fukushima
Hideyuki Ohshimo
Yuji Shimamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of ES2124257T3 publication Critical patent/ES2124257T3/es
Application granted granted Critical
Publication of ES2124257T4 publication Critical patent/ES2124257T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UNA COMPOSICION PARA POTENCIAR LA ACTIVIDAD ANTITUMORAL DEL TEGAFUR Y REDUCIR LOS SUS EFECTOS ADVERSOS, LA COMPOSICION COMPRENDE UN COMPUESTO REPRESENTADO POR LA FORMULA GENERAL (I) EN LA QUE X REPRESENTA HALOGENO O CIANO Y ACIDO OXONICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, ASI COMO UN METODO Y UN EQUIPO PARA EL USO DEL COMPUESTO, ASIMISMO SE PRESENTA UNA COMPOSICION PARA CURAR TUMORES QUE COMPRENDE TEGAFUR, UN COMPUESTO REPRESENTADO POR LA FORMULA (I) Y UN ACIDO OXONICO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; ASI COMO UN METODO Y UN EQUIPO PARA LOS MISMOS.
ES92910345T 1991-05-27 1992-05-22 Composición, método y equipo para la estimulación de la actividad antitumoral y para el tratamiento de tumores. Expired - Lifetime ES2124257T4 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP121247/91 1991-05-27
JP12124791 1991-05-27
PCT/JP1992/000656 WO1992021345A1 (en) 1991-05-27 1992-05-22 Composition, method and kit for potentiating antitumor activity and for curing tumor

Publications (2)

Publication Number Publication Date
ES2124257T3 true ES2124257T3 (es) 1999-02-01
ES2124257T4 ES2124257T4 (es) 2012-03-23

Family

ID=14806544

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910345T Expired - Lifetime ES2124257T4 (es) 1991-05-27 1992-05-22 Composición, método y equipo para la estimulación de la actividad antitumoral y para el tratamiento de tumores.

Country Status (14)

Country Link
US (1) US5525603A (es)
EP (1) EP0543015B1 (es)
JP (1) JP2614164B2 (es)
KR (1) KR0148589B1 (es)
AT (1) ATE173165T1 (es)
AU (1) AU654555B2 (es)
CA (1) CA2087540C (es)
DE (2) DE122011100040I2 (es)
DK (1) DK0543015T3 (es)
ES (1) ES2124257T4 (es)
HU (1) HU211987A9 (es)
LU (1) LU91852I2 (es)
TW (1) TW209833B (es)
WO (1) WO1992021345A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
JPH11116564A (ja) * 1997-10-09 1999-04-27 Otsuka Chem Co Ltd クロモン誘導体
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием
JP2002255828A (ja) * 2001-02-28 2002-09-11 Ajinomoto Co Inc 抗腫瘍剤
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
JP4610481B2 (ja) 2003-03-14 2011-01-12 大鵬薬品工業株式会社 抗腫瘍効果増強剤及び抗腫瘍剤
ME01335B (me) * 2004-04-29 2013-12-20 Taiho Pharmaceutical Co Ltd Postupak smanjenja gastrointestinalne toksičnosti usled administracije tegafura
KR100844477B1 (ko) 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
DE602006016576D1 (de) * 2005-04-01 2010-10-14 Taiho Pharmaceutical Co Ltd Strahlentherapieverstärker
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
CN101921227B (zh) * 2007-04-03 2012-09-05 南京工业大学 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
WO2010104035A1 (ja) 2009-03-12 2010-09-16 学校法人近畿大学 非小細胞肺癌に対する化学療法の治療効果予測方法
CN102369283A (zh) 2009-03-31 2012-03-07 德尔塔菲制药股份有限公司 靶向胸苷酸合酶的RNAi分子及其应用
US8992947B2 (en) 2009-04-22 2015-03-31 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of chemotherapy on renal cell cancer
EP2431032A4 (en) 2009-05-12 2012-11-07 Taiho Pharmaceutical Co Ltd ANTICROBIAL AGENTS WITH A TEGAFUR GIMERACIL OTERACIL CALIUM COMBINATION AND OXALIPLATIN
AU2010312594B2 (en) 2009-10-27 2013-06-20 Delta-Fly Pharma, Inc. Novel 5-fluorouracil derivative
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
JPWO2012105486A1 (ja) 2011-01-31 2014-07-03 大鵬薬品工業株式会社 １日１回隔日投与を特徴とするテガフール含有組成物
US9345767B2 (en) 2011-05-16 2016-05-24 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor
WO2012161240A1 (ja) 2011-05-25 2012-11-29 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠
CN103159673B (zh) * 2011-12-12 2015-02-04 山东新时代药业有限公司 一种制备吉美嘧啶的精制方法
JPWO2013137433A1 (ja) 2012-03-16 2015-08-03 大鵬薬品工業株式会社 ３剤を組み合わせた新規な抗腫瘍剤
TW201400810A (zh) * 2012-06-01 2014-01-01 大鵬藥品工業股份有限公司 對胃癌患者選擇化學療法之方法
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
JPS562913A (en) * 1979-06-21 1981-01-13 Ono Pharmaceut Co Ltd Antitumor agent
JPS5646867A (en) * 1979-09-25 1981-04-28 Ono Pharmaceut Co Ltd Pyridone derivative, its preparation and antineoplasmic agent
EP0180188B1 (en) * 1984-10-30 1992-04-15 Otsuka Pharmaceutical Co., Ltd. A composition for increasing the anti-cancer activity of an anti-cancer compound
JPS62155215A (ja) * 1984-11-30 1987-07-10 Otsuka Pharmaceut Co Ltd 抗腫瘍活性増強剤
NL194430C (nl) * 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
JPH0578249A (ja) * 1991-09-20 1993-03-30 Taiho Yakuhin Kogyo Kk ５−フルオロウラシル類により起こる嘔気・嘔吐の防止及び治療剤

Also Published As

Publication number Publication date
AU1791292A (en) 1993-01-08
DE122011100040I1 (de) 2011-11-24
WO1992021345A1 (en) 1992-12-10
ATE173165T1 (de) 1998-11-15
CA2087540C (en) 1999-01-19
KR0148589B1 (ko) 1998-11-02
CA2087540A1 (en) 1992-11-28
JP2614164B2 (ja) 1997-05-28
DE69227571D1 (de) 1998-12-17
LU91852I2 (fr) 2011-10-03
EP0543015A1 (en) 1993-05-26
AU654555B2 (en) 1994-11-10
DE69227571T2 (de) 1999-04-29
US5525603A (en) 1996-06-11
DE122011100040I2 (de) 2012-08-09
ES2124257T4 (es) 2012-03-23
EP0543015B1 (en) 1998-11-11
TW209833B (es) 1993-07-21
EP0543015A4 (en) 1994-06-01
DK0543015T3 (da) 1999-07-26
HU211987A9 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
ES2124257T3 (es) Composicion, metodo y equipo para la estimulacion de la actividad antitumoral y para el tratamiento de tumores.
ES2137932T3 (es) Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
ES2093694T3 (es) Nuevos derivados de dihidro-isoquinoleina.
ES525122A0 (es) Procedimiento para preparar derivados de piridina
ES8500276A1 (es) Procedimiento para preparar n2-acil-9-(1,3-dihidroxi-2-propoximetil)-guaninas y sus sales famaceuticamente aceptables.
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
DK339184A (da) Imidazoliumforbindelser, mellemprodukter hertil og fremgangsmaade til deres anvendelse
FI865233A0 (fi) Pyrazolinderivat, deras framstaellning och anvaendning som medel med insekticid och akaricid verkan.
ES8302025A1 (es) Procedimiento para la preparacion de 10-alquinil esteroides
ES2009723A4 (es) Derivados de acidos biliares, procedimientos para la preparacion de los mismos y composiciones farmaceuticas conteniendolos.
ATE116657T1 (de) 7-keto- und 7-hydroxy-androsta-3,5-dien-3- carbonsäure derivate.
ES8402297A1 (es) Un procedimiento de preparacion de derivados de imidazo-(1,2-)piridina.
IE830607L (en) Imidazolylphenylpyridazinones
ATE30583T1 (de) Vitamin-d3-derivate.
ES2091249T3 (es) Analogos de iludina utilizables como agentes antitumorales.
FI863565A0 (fi) Foerfarande foer framstaellning av nya pyrrobenzimidazoler, pyrrolbenzoxazoler och pyrrolbenztiazoler.
IT7809553A0 (it) Apparecchio per la respirazione artificiale comandato pneumaticamente per l approvvigionamento di emergenza
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
ES455691A1 (es) Procedimiento para la produccion de derivados de piperacina.
NO932722L (no) Salter av et 4-amino-3acyl-kinolinderivat og deres anvendelse som inhibatorer for gastrisk syresekresjon
ES8502435A1 (es) Un metodo para preparar 2(1h)-piridinonas
ES2000170A6 (es) Procedimiento para preparar 5,11-dihidro-6h-pirido(2,3-b)(1,4)-benzodiazepin-6-onas substituidas en posicion 11
DK218388A (da) Aktivt princip isoleret fra hajvaev
ES8504182A1 (es) Procedimiento para preparar nuevos derivados de piperidina
ES2064919T3 (es) Derivados del acido bifenil 5,5'-bis-alcanoico, su fabricacion y utilizacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 543015

Country of ref document: ES